Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers

被引：0

作者：

Narod, SA

Dubé, MP

Klijn, J

Lubinski, J

Lynch, HT

Ghadirian, P

Provencher, D

Heimdal, K

Moller, P

Robson, M

Offit, K

Isaacs, C

Weber, B

Friedman, E

Gershoni-Baruch, R

Rennert, G

Pasini, B

Wagner, T

Daly, M

Garber, JE

Neuhausen, SL

Ainsworth, P

Olsson, H

Evans, G

Osborne, M

Couch, F

Foulkes, WD

Warner, E

Kim-Sing, C

Olopade, O

Tung, N

Saal, HM

Weitzel, J

Merajver, S

Gauthier-Villars, M

Jernstrom, H

Sun, P

Brunet, JS

机构：

[1] Algorithme Pharma, Montreal, PQ, Canada

[2] Inst Curie, Sev Genet Oncol, Paris, France

[3] Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA

[4] City Hosp Hosp, Duarte, CA USA

[5] Childrens Hosp, Med Ctr, Div Human Genet, Hereditary Canc Program, Cincinnati, OH 45229 USA

[6] Beth Israel Deaconess Med Ctr, Boston, MA USA

[7] Univ Chicago, Ctr Clin Canc Genet, Chicago, IL 60637 USA

[8] British Columbia Canc Agcy, Vancouver, BC V5Z 4E6, Canada

[9] Sunnybrook & Womens Coll, Hlth Sci Ctr, Toronto, ON, Canada

[10] McGill Univ, Dept Oncol & Human Genet, Program Canc Genet, Montreal, PQ, Canada

[11] Mayo Clin, Rochester, MN USA

[12] Strang Canc Prevent Ctr, New York, NY USA

[13] St Marys Hosp, Manchester M13 0JH, Lancs, England

[14] Univ Lund Hosp, Dept Oncol, Jubileum Inst, S-22185 Lund, Sweden

[15] London Reg Canc Ctr, London, ON N6A 4L6, Canada

[16] Univ Utah, Dept Med Informat, Salt Lake City, UT 84112 USA

[17] Dana Farber Canc Inst, Boston, MA 02115 USA

[18] Fox Chase Canc Ctr, Div Populat Sci, Philadelphia, PA 19111 USA

[19] Univ Vienna, Dept Obstet & Gynecol, Vienna, Austria

[20] Ist Nazl Tumori, I-20133 Milan, Italy

[21] Carmel Hosp, Natl Canc Control Ctr, Haifa, Israel

[22] Rambam Med Ctr, Inst Genet, Haifa, Israel

[23] Chaim Sheba Med Ctr, Oncogenet Unit, IL-52621 Tel Hashomer, Israel

[24] Univ Penn, Dept Med, Philadelphia, PA 19104 USA

[25] Univ Penn, Dept Genet, Philadelphia, PA 19104 USA

[26] Georgetown Univ, Med Ctr, Lombardi Canc Ctr, Washington, DC 20007 USA

[27] Mem Sloan Kettering Canc Ctr, Dept Human Genet & Med, New York, NY 10021 USA

[28] Norwegian Radium Hosp, Dept Canc Genet, Oslo, Norway

[29] Norwegian Radium Hosp, Dept Canc Genet, Oslo, Norway

[30] Notre Dame Hosp, Dept Obstet & Gynecol, Montreal, PQ, Canada

[31] Univ Montreal, Hotel Dieu, CHUM, Epidemiol Res Unit, Montreal, PQ, Canada

[32] Creighton Univ, Sch Med, Dept Prevent Med & Publ Hlth, Omaha, NE USA

[33] Pomeranian Med Univ, Szczecin, Poland

[34] Erasmus Univ, Med Ctr, Rotterdam, Netherlands

[35] Dr Daniel Den Hoed Canc Ctr, NL-3008 AE Rotterdam, Netherlands

[36] Univ Toronto, Ctr Res Womens Hlth, Toronto, ON M5G 1N8, Canada

来源：

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE | 2002年 / 94卷 / 23期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background: Oral contraceptive use has been associated with an increase in the risk of breast cancer in young women. We examined whether this association is seen in women at high risk of breast cancer because they carry a mutation in one of two breast cancer susceptibility genes, BRCA1 and BRCA2. Methods: We performed a matched case-control study on 1311 pairs of women with known deleterious BRCA1 and/or BRCA2 mutations recruited from 52 centers in 11 countries. Women who had been diagnosed with breast cancer were matched to control subjects by year of birth, country of residence, mutation (BRCA1 or BRCA2), and history of ovarian cancer. All study subjects completed a questionnaire about oral contraceptive use. Odds ratios (ORs) and 95% confidence intervals (CIs) were derived by conditional logistic regression. All statistical tests were two-sided. Results: Among BRCA2 mutation carriers, ever use of oral contraceptives was not associated with an increased risk of breast cancer (OR = 0.94, 95% CI = 0.72 to 1.24). For BRCAI mutation carriers, ever use of oral contraceptives was associated With a modestly increased risk of breast cancer (OR = 1.20, 95 % CI = 1.02 to 1.40). However, compared with BRCA1 mutation carriers who never used oral contraceptives, those who used oral contraceptives for at least 5 years had an increased risk of breast cancer (OR = 1.33, 95% CI = 1.11 to 1.60), as did those who used oral contraceptives before age 30 (OR = 1.29, 95% CI = 1.09 to 1.52), those who were diagnosed with breast cancer before age 40 (OR = 1.38, 95% CI = 1.11 to 1.72), and those who first used oral contraceptives before 1975 (OR = 1.42, 95 % CI = 1.17 to 1.75). Conclusions: Among BRCA1 mutation carriers, women who first used oral contraceptives before 1975, who used them before age 30, or who used them for 5 or more years may have an increased risk of early-onset breast cancer. Oral contraceptives do not appear to be associated with risk of breast cancer in BRCA2 carriers, but data for BRCA2 carriers are limited.

引用

页码：1773 / 1779

页数：7

共 16 条

[1]

Calle EE, 1996, LANCET, V347, P1713, DOI 10.1016/S0140-6736(96)90806-5

[2] RISKS OF CANCER IN BRCA1-MUTATION CARRIERS [J].

FORD, D ;

EASTON, DF ;

BISHOP, DT ;

NAROD, SA ;

GOLDGAR, DE ;

HAITES, N ;

MILNER, B ;

ALLAN, L ;

PONDER, BAJ ;

PETO, J ;

SMITH, S ;

STRATTON, M ;

LENOIR, GM ;

FEUNTEUN, J ;

LYNCH, H ;

ARASON, A ;

BARKARDOTTIR, R ;

EGILSSON, V ;

BLACK, DM ;

KELSELL, D ;

SPURR, N ;

DEVILEE, P ;

CORNELISSE, CJ ;

VARSEN, H ;

BIRCH, JM ;

SKOLNICK, M ;

SANTIBANEZKOREF, MS ;

TEARE, D ;

STEEL, M ;

PORTER, D ;

COHEN, BB ;

CAROTHERS, A ;

SMYTH, E ;

WEBER, B ;

NEWBOLD, B ;

BOEHNKE, M ;

COLLINS, FS ;

CANNONALBRIGHT, LA ;

GOLDGAR, D .

LANCET, 1994, 343 (8899) :692-695

[3] Risk of breast cancer with oral contraceptive use in women with a family history of breast cancer [J].

Gabrick, DM ;

Hartmann, LC ;

Cerhan, JR ;

Vierkant, RA ;

Therneau, TM ;

Vachon, CM ;

Olson, JE ;

Couch, FJ ;

Anderson, KE ;

Pankratz, VS ;

Sellers, TA .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2000, 284 (14) :1791-1798

[4] Pregnancy and risk of early breast cancer in carriers of BRCA1 and BRCA2 [J].

Jernström, H ;

Lerman, C ;

Ghadirian, P ;

Lynch, HT ;

Weber, B ;

Garber, J ;

Daly, M ;

Olopade, OI ;

Foulkes, WD ;

Warner, E ;

Brunet, JS ;

Narod, SA .

LANCET, 1999, 354 (9193) :1846-1850

[5] Tumour biological features of BRCA1-induced breast and ovarian cancer [J].

Johannsson, OT ;

Idvall, I ;

Anderson, C ;

Borg, A ;

Barkardottir, RB ;

Egilsson, V ;

Olsson, H .

EUROPEAN JOURNAL OF CANCER, 1997, 33 (03) :362-371

[6]

Karp SE, 1997, CANCER-AM CANCER SOC, V80, P435, DOI 10.1002/(SICI)1097-0142(19970801)80:3<435::AID-CNCR11>3.0.CO

[7]

2-Y

[8] Cancer incidence in a population of Jewish women at risk of ovarian cancer [J].

Liede, A ;

Karlan, BY ;

Baldwin, RL ;

Platt, LD ;

Kuperstein, G ;

Narod, SA .

JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (06) :1570-1577

[9] Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. [J].

Meijers-Heijboer, H ;

van Geel, B ;

van Putten, WLJ ;

Henzen-Logmans, SC ;

Seynaeve, C ;

Menke-Pluymers, MBE ;

Bartels, CCM ;

Verhoog, LC ;

van den Ouweland, AMW ;

Niermeijer, MF ;

Brekelmans, CTM ;

Klijn, JGM .

NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (03) :159-164

[10] Parity, oral contraceptives, and the risk of ovarian cancer among carriers and noncarriers of a BRCA1 or BRCA2 mutation [J].

Modan, B ;

Hartge, P ;

Hirsh-Yechezkel, G ;

Chetrit, A ;

Lubin, F ;

Beller, U ;

Ben-Baruch, G ;

Fishman, A ;

Menczer, J ;

Struewing, JP ;

Tucker, MA ;

Wacholder, S ;

Ebbers, SM ;

Friedman, E ;

Piura, B .

NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (04) :235-240

← 1 2 →